Anna Berkenblit

SVP and Chief Medical Officer

Dr Anna Berkenblit joined ImmunoGen in 2015 and is responsible for leading the clinical development of ImmunoGen’s novel, wholly owned product candidates. She has extensive experience in the clinical development of novel anticancer therapies, including five years heading clinical research at two oncology-focused companies. Prior to joining ImmunoGen, Dr Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine, a developer of targeted anticancer compounds founded by Eisai Pharmaceuticals. Prior to H3 Biomedicine, she was VP, Head of Clinical Research at AVEO Oncology, where she led the clinical development of oncology product candidates spanning early testing to registration trials.Prior to AVEO, Dr Berkenblit held positions of increasing responsibility at Wyeth and then Pfizer, becoming Vice President, Neratinib Asset Team Leader in the Pfizer Oncology Business Unit. Dr Berkenblit earned an MD degree from Harvard Medical School, and an MMSc degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences & Technology. She completed her internship and residency at Brigham and Women’s Hospital, then went on to a hematology/oncology fellowship at Beth Israel Deaconess Medical Center where she stayed on staff to focus on clinical research in GYN and GI malignancies. She also led the Phase I oncology clinical trial program as part of the Dana-Farber/Harvard Cancer Center, prior to transitioning to industry. Dr Berkenblit currently serves on the Board of Directors of Surrozen, Inc.

Talks About
#ClinicalResearch #Medicine #ClinicalDevelopment

Preferred Locations
#UnitedStates